Mural Oncology plc (MURA)

Data as of Dec 5, 2025, from SEC Form 4 filings.

No open-market insider trades (90d)Watch MURA

See up to 3 months of MURA. The 7-day demo opens the 1M and 3M ranges and puts MURA on your watchlist.

Latest MURA insider trades

Adam D. Cutler - Officer
Open-market sale$15K
Nov 3, 2025
Vicki L. Goodman - Officer
Open-market sale$10K
Nov 10, 2025

About Mural Oncology plc (MURA)

Mural Oncology plc is an SEC registrant, filing under CIK 0001971543, classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.

Sector: Health Care

SEC filings for MURA on EDGAR

MURA Form 4 activity by transaction type, last 90 days

No Form 4 activity for MURA in the last 90 days.

MURA insider transactions (Form 4)

18 Form 4 filings on record, the earliest from Nov 1, 2024, newest first.

Date	Insider	Transaction	Security	Shares	Price	Value
Dec 5, 2025	Caroline Loew - Officer	Derivative	Ordinary Shares	293,059^{footnote F1,F2}	-^{footnote F1,F2}	-
Dec 5, 2025	Caroline Loew - Officer	Derivative	Stock Option (right to buy)	379,690	-^{footnote F3}	-
Dec 5, 2025	Caroline Loew - Officer	Derivative	Stock Option (right to buy)	90,025	-^{footnote F3}	-
Dec 5, 2025	Caroline Loew - Officer	Derivative	Stock Option (right to buy)	134,225	-^{footnote F3}	-
Footnote F1 (price, shares): Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be… Full note on SEC EDGAR Footnote F2 (price, shares): Includes the disposition of 220,148 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically… Full note on SEC EDGAR Footnote F3 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR
Dec 5, 2025	Francis M. Cuss	Derivative	Stock Option (right to buy)	8,637	-^{footnote F2}	-
Dec 5, 2025	Francis M. Cuss	Derivative	Stock Option (right to buy)	8,462	-^{footnote F2}	-
Dec 5, 2025	Francis M. Cuss	Derivative	Stock Option (right to buy)	15,021	-^{footnote F2}	-
Footnote F2 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR
Dec 5, 2025	Vicki L. Goodman - Officer	Derivative	Ordinary Shares	84,727^{footnote F1,F2}	-^{footnote F1,F2}	-
Dec 5, 2025	Vicki L. Goodman - Officer	Derivative	Stock Option (right to buy)	135,604	-^{footnote F3}	-
Dec 5, 2025	Vicki L. Goodman - Officer	Derivative	Stock Option (right to buy)	65,000	-^{footnote F3}	-
Footnote F1 (price, shares): Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be… Full note on SEC EDGAR Footnote F2 (price, shares): Includes the disposition of 71,509 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically… Full note on SEC EDGAR Footnote F3 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR
Dec 5, 2025	Sachiyo Minegishi	Derivative	Stock Option (right to buy)	8,637	-^{footnote F2}	-
Dec 5, 2025	Sachiyo Minegishi	Derivative	Stock Option (right to buy)	15,335	-^{footnote F2}	-
Footnote F2 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR
Dec 5, 2025	Benjamin Hickey	Derivative	Stock Option (right to buy)	8,637	-^{footnote F2}	-
Dec 5, 2025	Benjamin Hickey	Derivative	Stock Option (right to buy)	8,462	-^{footnote F2}	-
Dec 5, 2025	Benjamin Hickey	Derivative	Stock Option (right to buy)	15,021	-^{footnote F2}	-
Footnote F2 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR
Dec 5, 2025	Adam D. Cutler - Officer	Derivative	Ordinary Shares	99,290^{footnote F1,F2}	-^{footnote F1,F2}	-
Dec 5, 2025	Adam D. Cutler - Officer	Derivative	Stock Option (right to buy)	146,452	-^{footnote F3}	-
Dec 5, 2025	Adam D. Cutler - Officer	Derivative	Stock Option (right to buy)	65,000	-^{footnote F3}	-
Footnote F1 (price, shares): Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be… Full note on SEC EDGAR Footnote F2 (price, shares): Includes the disposition of 77,429 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically… Full note on SEC EDGAR Footnote F3 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR
Dec 5, 2025	Maiken Keson-Brookes - Officer	Derivative	Ordinary Shares	68,834^{footnote F1,F2}	-^{footnote F1,F2}	-
Dec 5, 2025	Maiken Keson-Brookes - Officer	Derivative	Stock Option (right to buy)	54,242	-^{footnote F3}	-
Dec 5, 2025	Maiken Keson-Brookes - Officer	Derivative	Stock Option (right to buy)	31,200	-^{footnote F3}	-
Dec 5, 2025	Maiken Keson-Brookes - Officer	Derivative	Stock Option (right to buy)	65,000	-^{footnote F3}	-
Footnote F1 (price, shares): Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be… Full note on SEC EDGAR Footnote F2 (price, shares): Includes the disposition of 62,203 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically… Full note on SEC EDGAR Footnote F3 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR
Dec 5, 2025	George Golumbeski	Derivative	Stock Option (right to buy)	8,637	-^{footnote F2}	-
Dec 5, 2025	George Golumbeski	Derivative	Stock Option (right to buy)	15,334	-^{footnote F2}	-
Footnote F2 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR
Dec 5, 2025	Scott Thomas Jackson	Derivative	Stock Option (right to buy)	8,637	-^{footnote F2}	-
Dec 5, 2025	Scott Thomas Jackson	Derivative	Stock Option (right to buy)	8,462	-^{footnote F2}	-
Dec 5, 2025	Scott Thomas Jackson	Derivative	Stock Option (right to buy)	15,021	-^{footnote F2}	-
Footnote F2 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR
Nov 3, 2025	Adam D. Cutler - Officer	Open-market sale	Ordinary Shares	7,148	$2.09	$15K
Nov 10, 2025	Vicki L. Goodman - Officer	Open-market sale	Ordinary Shares	5,036	$2.08	$10K
Jul 22, 2025	Maiken Keson-Brookes - Officer	Open-market sale	Ordinary Shares	2,572	$2.48	$6K
Jul 18, 2025	Maiken Keson-Brookes - Officer	Open-market sale	Ordinary Shares	2,158	$2.48	$5K
Jul 7, 2025	Caroline Loew - Officer	Open-market sale	Ordinary Shares	12,531	$2.43	$30K
Dec 23, 2024	Maiken Keson-Brookes - Officer	Open-market sale	Ordinary Shares	2,555	$3.27	$8K
Dec 17, 2024	Caroline Loew - Officer	Open-market sale	Ordinary Shares	2,763	$3.40	$9K
Nov 7, 2024	Vicki L. Goodman - Officer	Open-market sale	Ordinary Shares	5,069	$3.33	$17K
Oct 31, 2024	Adam D. Cutler - Officer	Open-market sale	Ordinary Shares	7,421	$3.41	$25K

MURA insider trading FAQ

What is the latest insider trade for MURA?

Mural Oncology plc (MURA) has filed no insider reports in the last 90 days. The most recent on record is dated 2025-12-05. The full record for MURA runs to 18 Form 4 filings, the earliest from 2024-11-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying MURA stock?

No insider purchases of MURA were filed in the last 90 days.

How many insiders are selling MURA stock?

No insider sales of MURA were filed in the last 90 days. 9 sales are on record for this company.

Where can I see MURA SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects MURA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Dec 5, 2025 - Caroline Loew view on EDGAR
Dec 5, 2025 - Francis M. Cuss view on EDGAR
Dec 5, 2025 - Vicki L. Goodman view on EDGAR
Dec 5, 2025 - Sachiyo Minegishi view on EDGAR
Dec 5, 2025 - Benjamin Hickey view on EDGAR
Dec 5, 2025 - Adam D. Cutler view on EDGAR
Dec 5, 2025 - Maiken Keson-Brookes view on EDGAR
Dec 5, 2025 - George Golumbeski view on EDGAR
Dec 5, 2025 - Scott Thomas Jackson view on EDGAR
Nov 10, 2025 - Adam D. Cutler view on EDGAR

Related companies with recent insider activity

Learn more

What the Form 4 transaction codes mean: Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
Insider activity in Health Care: Where MURA's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow MURA with a 7-day demo

MURA on your watchlist
Every MURA Form 4 filing on record
Up to 3 months of MURA price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Date

Insider

Transaction

Security

Price

Value

Dec 5, 2025

Caroline Loew - Officer

Derivative

Ordinary Shares

293,059^{footnote F1,F2}

-^{footnote F1,F2}

Dec 5, 2025

Caroline Loew - Officer

Derivative

Stock Option (right to buy)

379,690

-^{footnote F3}

Dec 5, 2025

Caroline Loew - Officer

Derivative

Stock Option (right to buy)

90,025

-^{footnote F3}

Dec 5, 2025

Caroline Loew - Officer

Derivative

Stock Option (right to buy)

134,225

-^{footnote F3}

Footnote F1 (price, shares): Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be… Full note on SEC EDGAR
Footnote F2 (price, shares): Includes the disposition of 220,148 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically… Full note on SEC EDGAR
Footnote F3 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR

Dec 5, 2025

Francis M. Cuss

Derivative

Stock Option (right to buy)

8,637

-^{footnote F2}

Dec 5, 2025

Francis M. Cuss

Derivative

Stock Option (right to buy)

8,462

-^{footnote F2}

Dec 5, 2025

Francis M. Cuss

Derivative

Stock Option (right to buy)

15,021

-^{footnote F2}

Footnote F2 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR

Dec 5, 2025

Vicki L. Goodman - Officer

Derivative

Ordinary Shares

84,727^{footnote F1,F2}

-^{footnote F1,F2}

Dec 5, 2025

Vicki L. Goodman - Officer

Derivative

Stock Option (right to buy)

135,604

-^{footnote F3}

Dec 5, 2025

Vicki L. Goodman - Officer

Derivative

Stock Option (right to buy)

65,000

-^{footnote F3}

Footnote F1 (price, shares): Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be… Full note on SEC EDGAR
Footnote F2 (price, shares): Includes the disposition of 71,509 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically… Full note on SEC EDGAR
Footnote F3 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR

Dec 5, 2025

Sachiyo Minegishi

Derivative

Stock Option (right to buy)

8,637

-^{footnote F2}

Dec 5, 2025

Sachiyo Minegishi

Derivative

Stock Option (right to buy)

15,335

-^{footnote F2}

Footnote F2 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR

Dec 5, 2025

Benjamin Hickey

Derivative

Stock Option (right to buy)

8,637

-^{footnote F2}

Dec 5, 2025

Benjamin Hickey

Derivative

Stock Option (right to buy)

8,462

-^{footnote F2}

Dec 5, 2025

Benjamin Hickey

Derivative

Stock Option (right to buy)

15,021

-^{footnote F2}

Footnote F2 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR

Dec 5, 2025

Adam D. Cutler - Officer

Derivative

Ordinary Shares

99,290^{footnote F1,F2}

-^{footnote F1,F2}

Dec 5, 2025

Adam D. Cutler - Officer

Derivative

Stock Option (right to buy)

146,452

-^{footnote F3}

Dec 5, 2025

Adam D. Cutler - Officer

Derivative

Stock Option (right to buy)

65,000

-^{footnote F3}

Footnote F1 (price, shares): Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be… Full note on SEC EDGAR
Footnote F2 (price, shares): Includes the disposition of 77,429 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically… Full note on SEC EDGAR
Footnote F3 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR

Dec 5, 2025

Maiken Keson-Brookes - Officer

Derivative

Ordinary Shares

68,834^{footnote F1,F2}

-^{footnote F1,F2}

Dec 5, 2025

Maiken Keson-Brookes - Officer

Derivative

Stock Option (right to buy)

54,242

-^{footnote F3}

Dec 5, 2025

Maiken Keson-Brookes - Officer

Derivative

Stock Option (right to buy)

31,200

-^{footnote F3}

Dec 5, 2025

Maiken Keson-Brookes - Officer

Derivative

Stock Option (right to buy)

65,000

-^{footnote F3}

Footnote F1 (price, shares): Pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, Sub acquired all the issued and to be… Full note on SEC EDGAR
Footnote F2 (price, shares): Includes the disposition of 62,203 unvested restricted stock units ("RSUs"). Pursuant to the Agreement, as of the Effective Time each RSU held by the Reporting Person that was outstanding as of immediately prior to the Effective Time (whether or not vested) was automatically… Full note on SEC EDGAR
Footnote F3 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR

Dec 5, 2025

George Golumbeski

Derivative

Stock Option (right to buy)

8,637

-^{footnote F2}

Dec 5, 2025

George Golumbeski

Derivative

Stock Option (right to buy)

15,334

-^{footnote F2}

Footnote F2 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR

Dec 5, 2025

Scott Thomas Jackson

Derivative

Stock Option (right to buy)

8,637

-^{footnote F2}

Dec 5, 2025

Scott Thomas Jackson

Derivative

Stock Option (right to buy)

8,462

-^{footnote F2}

Dec 5, 2025

Scott Thomas Jackson

Derivative

Stock Option (right to buy)

15,021

-^{footnote F2}

Footnote F2 (price): Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration… Full note on SEC EDGAR

Nov 3, 2025

Adam D. Cutler - Officer

Open-market sale

Ordinary Shares

7,148

$2.09

$15K

Nov 10, 2025

Vicki L. Goodman - Officer

Open-market sale

Ordinary Shares

5,036

$2.08

$10K

Jul 22, 2025

Maiken Keson-Brookes - Officer

Open-market sale

Ordinary Shares

2,572

$2.48

$6K

Jul 18, 2025

Maiken Keson-Brookes - Officer

Open-market sale

Ordinary Shares

2,158

$2.48

$5K

Jul 7, 2025

Caroline Loew - Officer

Open-market sale

Ordinary Shares

12,531

$2.43

$30K

Dec 23, 2024

Maiken Keson-Brookes - Officer

Open-market sale

Ordinary Shares

2,555

$3.27

$8K

Dec 17, 2024

Caroline Loew - Officer

Open-market sale

Ordinary Shares

2,763

$3.40

$9K

Nov 7, 2024

Vicki L. Goodman - Officer

Open-market sale

Ordinary Shares

5,069

$3.33

$17K

Oct 31, 2024

Adam D. Cutler - Officer

Open-market sale

Ordinary Shares

7,421

$3.41

$25K